nanoparticles
(3)
Karl Ruping
Karl Ruping is the founder and CEO of Tiba Biotech, a Cambridge, Massachusetts company developing biodegradable nanoparticle delivery systems for RNA vaccines and therapeutics. He also runs incTANK Ventures, a seed fund spun out of MIT and Boston-area research labs, and sits at Harvard's Asia Center as an associate working on international patent policy. Lawyer, computational scientist, financier, and operator wrapped into one resume.
Gene Dolgoff
Gene Dolgoff is the founder, CEO, CTO, and Chairman of Holobeam Technologies, a Long Island biotech building holographic tools to detect and treat cancer. He has been making holograms since 1964, holds over 65 patents worldwide, built the world's first LCD projector, and consulted with Gene Roddenberry on the concept that became the Star Trek Holodeck. Today his company is developing Holographic Energy Teleportation (HET), advanced nanoparticles, and a new class of MRI imaging - aiming, in his words, to teleport energy through the body to kill cancer cells.
Aihua Fu
Aihua Fu is a nanobiotechnologist and the co-founder, President and CEO of NVIGEN Inc., a San Jose nanobiotechnology company building molecularly engineered magnetic and fluorescent nanoparticles for cancer detection and personalized medicine. Trained as a chemist under Nobel-track nanoscience pioneer A. Paul Alivisatos at UC Berkeley and as a postdoc at Stanford, she turned quantum-dot and magnetic-bead research into commercial tools for liquid biopsy, cfDNA extraction, single-cell sequencing and circulating tumor cell capture. Her flagship NVIGEN X and NERNST-Seq platforms aim to read DNA, RNA, protein and cell signals together to predict cancer recurrence early and guide therapy.